How We Lead – Perspectives from Two Key Biotechnology Hubs in North America

March 8, 2021 11:30 AM - 1:15 PM

Webinar, click "live-stream" button to view

Add to Calendar 3/8/2021 11:30:00 AM 3/8/2021 1:15:00 PM How We Lead – Perspectives from Two Key Biotechnology Hubs in North America

Join us on International Women’s Day, March 8, 2021, when WIB-Greater Montreal and WIB-Greater Boston will present a joint event with BIOQuébec and MassBio.

BIOQuébec is committed to supporting Québec’s biotechnology and life sciences industry. MassBio’s mission is to advance Massachusetts’ leadership in the life sciences and each is dedicated to improving healthcare and quality of life. Join the discussion of the landscape in Quebec and Massachusetts and biotech leaders’ perspectives on challenges/obstacles faced, leadership styles, where do we want to be, and how do we get there.

The event will be facilitated by journalist-columnist Tasha Kheiriddin with panelists from Québec: Anie Perrault, executive director BIOQuébec, Clarissa Desjardins, founder and former CEO, Clementia (now Ipsen), and Nadine Beauger, President & CEO, IRICOR and from Massachusetts: Kendalle Burin O’Connell, President & COO MassBio, Ramani Varanasi- President & CEO of X-Biotix Therapeutics, and Liang Schweizer- CEO & CSO of HiFiBiO Therapeutics.

PLEASE NOTE: You will be redirected to the Women In Bio event page by clicking, "Register Now." This event requires you to sign-in to receive a personalized link to the webinar. Please select “sign-in” and then choose “non-member.” The event is free for all MassBio members.

Disclaimer: This event may be recorded. There is a possibility your image and/or voice may be a part of that recording. If you are uncomfortable, please be sure to turn off your webcam.

 Webinar, click "live-stream" button to view
Board Member, Insmed Incorporated
Dr. Clarissa Desjardins founded and was the CEO of Clementia, a Montreal-based company focused on developing therapies for rare pediatric bone diseases. Clementia has offices in Montreal and Boston and was Nasdaq-listed company until its acquisition by Ipsen in early 2019 for $1.3 billion dollars. Continuing to operate in Montreal, Clementia is advancing a Phase 3 trial in fibrodysplasia ossificans progressiva (FOP) and a phase 2 trial in multiple osteochondroma. The company is also preparing to submit a New Drug Application (NDA) for FOP to the FDA in 2021. Dr. Desjardins is an award-winning entrepreneur with more than 25 years of biotechnology experience. She has founded three successful biotech companies, leading all aspects of company creation including conception and financing. She founded Advanced Bioconcept, a research reagent and diagnostics company sold to NEN Life Sciences (Perkin Elmer) in 1998. Dr. Desjardins also co-founded Caprion Pharmaceuticals, a biotechnology company focused on proteomic biomarker discovery and drug development, where she was Executive Vice-President of corporate development. Prior to Clementia, Clarissa was CEO at the Centre d’excellence en médecine personnalisée (CEPMED), a Montreal-based non-profit organization created to promote personalized medicine. Dr. Desjardins is the recipient of the 2018 Bloom Burton Award for her contribution to Canada’s innovative healthcare industry, the BRIO award for outstanding contributions to the biotechnology industry from the Quebec Biotechnology Association and was named one of 2017’s Fiercest Women in Life Sciences by FiercePharma. Dr. Desjardins currently sits on the board of BELLUS Health, INSMED and Xenon. Dr. Desjardins earned a doctorate in neurology and neurosurgery from McGill University’s Faculty of Medicine.